DC:BAVA Bavarian Nordic A/S
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; and Biomedical Advanced Research and Development Authority. It also has a license and collaboration agreement with Janssen Pharmaceuticals, Inc. to leverage its MVA-BN technology with Janssen's AdVac and DNA-based vaccine technologies for the development and commercialization of new vaccine regimens against hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1). The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.This company has ADRs that trade in the U.S. as the symbol BVNRY.
182.50 EUR
As of 03/24/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Biotechnology
Index country: Denmark
Country of incorporation: Denmark
IPO date: 10/16/2000
Stock exchange: Omx Nordic Exchange Copen
Exchange country: Denmark
Market cap: 12,896,539,648 EUR
Current dividend yield: 0.00%
Sedol: 5564619